All Cancer articles – Page 5
-
PodcastAflatoxins
Kat Arney investigates the cancer-causing chemicals that could be lurking in that bag of peanuts
-
BusinessJudges overturn J&J talc cancer claims
Two new rulings follow trend of reversing large jury-awarded damages as firm works through thousands of cases
-
BusinessUS to invest $160m in cancer partnership
Funds will be backed up with $55m from 11 companies to advance new cancer treatments that harness the immune system
-
ResearchRoute to fiendishly complex marine molecule cut in half
Shortcut to promising natural product already in Alzheimer’s and HIV trials
-
BusinessAmgen partners to launch biosimilars in China
US biopharma and Chinese generics firm will co-develop medicines from Amgen’s pipeline focused on inflammation and oncology
-
ReviewExhibition: Open for discovery
The Francis Crick Institute’s first exhibition showcases its scientists’ research
-
BusinessCelgene pays $280m to settle off-label marketing lawsuit
Whistleblower case relating to cancer prescriptions
-
BusinessLilly wins chemotherapy patent appeal
Firm also settles with generic manufacturers of erectile dysfunction drug Cialis
-
BusinessCelgene and BeiGene agree cancer partnership
Immuno-oncology deal sees firms exchange licensing rights for antibody drugs
-
PodcastCaesium chloride
A compound found in mineral water that is also used in medical treatments and solar cells
-
NewsEuropean chemicals body links titanium dioxide to cancer
Chemical found in everything from paint to toothpaste added to list of suspected carcinogens over inhalation risk
-
BusinessFirst biomarker-driven approval exemplifies cancer immunotherapy progress
Landmark decision is latest step in field’s impressive – but not wholly untroubled – advance
-
BusinessSeattle Genetics cancels Immunomedics deal
Settlement also resolves disputes with shareholders
-
BusinessJ&J fights talc cancer claims
Firm has lost several court cases linking talc to ovarian cancer, but vows to appeal
-
NewsEx-Harvard postdoc sues university for drug royalties
Former Harvard chemist says he lost out on millions after the technology he worked on was licensed to Merck & Co
-
NewsAction on white asbestos blocked by top exporters
Chrysotile will not be added to Rotterdam Convention’s list of hazardous substances
-
BusinessExpanding precision medicine beyond cancer
Exclusive interview with Koustubh Ranade, vice president of R&D at MedImmune
-
NewsGlyphosate is not carcinogenic, EU chemicals association concludes
Evaluation clears the way for long term authorisation of herbicide
-
-
BusinessUniversity–industry collaborations aspire to pharmaceutical innovation
Three new UK partnerships illustrate drug research co-operation approaches that are growing in popularity